Michael Kasperkiewicz

Summary

Country: Germany

Publications

  1. ncbi request reprint The pathophysiology of bullous pemphigoid
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Ratzeburger Allee 160, 23538, Lubeck, Germany
    Clin Rev Allergy Immunol 33:67-77. 2007
  2. pmc Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid
    Stefan Tukaj
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    PLoS ONE 8:e70496. 2013
  3. ncbi request reprint Pemphigus herpetiformis: from first description until now
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany Electronic address
    J Am Acad Dermatol 70:780-7. 2014
  4. doi request reprint Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Germany
    J Pathol 228:8-19. 2012
  5. doi request reprint Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    J Am Acad Dermatol 66:583-8. 2012
  6. doi request reprint Current therapy of the pemphigus group
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Germany
    Clin Dermatol 30:84-94. 2012
  7. doi request reprint Pemphigoid diseases: pathogenesis, diagnosis, and treatment
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    Autoimmunity 45:55-70. 2012
  8. doi request reprint Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients
    M Kasperkiewicz
    Departments of Dermatology Medicine Comprehensive Centre for Inflammation Medicine, University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Br J Dermatol 166:154-60. 2012
  9. ncbi request reprint [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases]
    M Kasperkiewicz
    Klinik fur Dermatologie, Allergologie und Venerologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck
    Hautarzt 58:115-6, 118-21. 2007
  10. doi request reprint Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    J Am Acad Dermatol 65:552-8. 2011

Detail Information

Publications19

  1. ncbi request reprint The pathophysiology of bullous pemphigoid
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Ratzeburger Allee 160, 23538, Lubeck, Germany
    Clin Rev Allergy Immunol 33:67-77. 2007
    ..The loss of cell-matrix adhesion is mediated by proteinases released by granulocytes. The increased knowledge of the pathophysiology of BP should facilitate the development of novel therapeutic strategies for this disease...
  2. pmc Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid
    Stefan Tukaj
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    PLoS ONE 8:e70496. 2013
    ..These findings suggest that Hsp90 may play a pathophysiological role and represent a novel potential treatment target in BP. ..
  3. ncbi request reprint Pemphigus herpetiformis: from first description until now
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany Electronic address
    J Am Acad Dermatol 70:780-7. 2014
    ....
  4. doi request reprint Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Germany
    J Pathol 228:8-19. 2012
    ..Our findings both genetically and functionally identify a novel disease-related molecule, FcγRIV, in an autoantibody-mediated disorder, which may be of importance for the development of novel targeted therapies...
  5. doi request reprint Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    J Am Acad Dermatol 66:583-8. 2012
    ..Recently, a novel serologic assay using deamidated gliadin-analogous fusion peptides (GAF3X) showed high diagnostic sensitivity in patients with CD...
  6. doi request reprint Current therapy of the pemphigus group
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Germany
    Clin Dermatol 30:84-94. 2012
    ..This contribution covers both conventional therapies and most current treatment strategies for pemphigus...
  7. doi request reprint Pemphigoid diseases: pathogenesis, diagnosis, and treatment
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    Autoimmunity 45:55-70. 2012
    ..This review covers the most recent understanding of the pathophysiology, diagnosis, and treatment of this group of autoimmune diseases...
  8. doi request reprint Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients
    M Kasperkiewicz
    Departments of Dermatology Medicine Comprehensive Centre for Inflammation Medicine, University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Br J Dermatol 166:154-60. 2012
    ....
  9. ncbi request reprint [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases]
    M Kasperkiewicz
    Klinik fur Dermatologie, Allergologie und Venerologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck
    Hautarzt 58:115-6, 118-21. 2007
    ..Randomized controlled trials are necessary to better determine the efficacy and adverse effects of rituximab in the treatment of autoimmune blistering diseases...
  10. doi request reprint Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    J Am Acad Dermatol 65:552-8. 2011
    ..However, only a few larger case series are available on this subject and information on the efficacy of retreatment with rituximab during relapses is lacking...
  11. doi request reprint Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    Blood 117:6135-42. 2011
    ..Our results suggest that Hsp90 blockade has no impact on normal or autoreactive plasma cells in vivo and indentify T cells as targets of anti-Hsp90 treatment in autoimmunity to type VII collagen...
  12. doi request reprint Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita
    M Kasperkiewicz
    Department of Dermatology, University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Br J Dermatol 162:1064-70. 2010
    ..However, little is known about their natural clearance rates in these different compartments...
  13. doi request reprint Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita
    Ralf J Ludwig
    Department of Dermatology, University of Lubeck, Lubeck, Germany
    J Invest Dermatol 131:167-76. 2011
    ..Furthermore, our data are the basis for future studies with the goal of identifying non-MHC EBA susceptibility genes...
  14. doi request reprint Immunoadsorption in dermatology
    Damian Meyersburg
    Departments of Dermatology Comprehensive Centre for Inflammation Medicine, University of Lubeck, Lubeck, Germany
    Ther Apher Dial 16:311-20. 2012
    ..Most recently, IA has been successfully applied in patients with severe atopic dermatitis and high total serum IgE levels. Here, the different treatment protocols, clinical efficacy, and adverse events are summarized...
  15. doi request reprint Animal models for autoimmune bullous dermatoses
    Katja Bieber
    Institute of Anatomy, University of Lubeck, Lubeck, Germany
    Exp Dermatol 19:2-11. 2010
    ..We here review established and novel animal models of autoimmune skin blistering diseases and discuss their applications and limitations...
  16. pmc Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy
    Nina van Beek
    Department of Dermatology, University of Luebeck, Luebeck, Germany
    Orphanet J Rare Dis 7:49. 2012
    ..BIOCHIP mosaics consisting of different antigen substrates allow polyvalent immunofluorescence (IF) tests and provide antibody profiles in a single incubation...
  17. doi request reprint Linear IgA disease: successful application of immunoadsorption and review of the literature
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Lubeck, Germany michael kasperkiewicz uk sh de
    Dermatology 220:259-63. 2010
    ..Here, we report a patient with a severe generalized LAD in whom adjuvant tryptophan IA was associated with rapid healing of skin lesions. Our observation suggests that IA may also be a helpful adjuvant treatment option for severe LAD...
  18. ncbi request reprint Current treatment of autoimmune blistering diseases
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Ratzeburger Allee 160, D 23562 Lubeck, Germany
    Curr Drug Discov Technol 6:270-80. 2009
    ..Here, both conventional therapies and novel treatment regimens for autoimmune blistering diseases are discussed...
  19. doi request reprint Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Ratzeburger Allee 160, Lubeck, Germany
    J Dtsch Dermatol Ges 10:727-32. 2012
    ..However, no systematic evaluation is available to corroborate this observation. The aim of this study was to systematically determine efficacy and safety of rituximab in treatment-resistant pemphigus...